Analysts at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN – Get Rating) in a note issued to investors on Wednesday. The firm set a “sell” rating on the medical research company’s stock.
A number of other equities research analysts also recently weighed in on OPGN. Alliance Global Partners downgraded OpGen to a “neutral” rating in a report on Tuesday, July 19th. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of OpGen in a report on Friday, June 10th.
OpGen Price Performance
Shares of OPGN opened at $0.43 on Wednesday. OpGen has a 1 year low of $0.31 and a 1 year high of $3.55. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.40 and a quick ratio of 1.32. The company has a market capitalization of $20.78 million, a price-to-earnings ratio of -0.54 and a beta of -0.37. The business has a 50-day moving average of $0.52 and a 200-day moving average of $0.58.
Institutional Investors Weigh In On OpGen
An institutional investor recently raised its position in OpGen stock. Arete Wealth Advisors LLC grew its position in shares of OpGen, Inc. (NASDAQ:OPGN – Get Rating) by 70.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 85,000 shares of the medical research company’s stock after acquiring an additional 35,000 shares during the quarter. Arete Wealth Advisors LLC owned about 0.18% of OpGen worth $64,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 7.24% of the company’s stock.
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
- Get a free copy of the StockNews.com research report on OpGen (OPGN)
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It’s a Down Week
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.